Next-generation clinical data application
harmonizes data for efficiency and speed
BARCELONA, Spain, Aug. 31, 2023 /PRNewswire/ -- Veeva Clinical
Database (CDB) enables innovative ways of managing clinical trial
data, saving customers 30 to 50% of the time required to aggregate,
clean, and transform data. Since Veeva Systems (NYSE: VEEV)
announced its launch, Veeva CDB has cleaned more than 200,000
subjects to quickly provide quality data across more than 200
studies.
"By launching Veeva CDB and building processes around it, we're
laying a foundation for clinical data transformation," said
Jerry Yarem, vice president, data
management, Fortrea. "This is a significant advancement that can
bring together all of our data sources and deliver clean data
faster than ever so study teams can make data-driven decisions with
confidence."
Veeva CDB automates processes for a new way of cleaning data
that increases productivity and efficiency. Using Veeva CDB Auto
Checks, customers can automatically identify discrepancies upon
data ingestion and create queries or close them when issues are
corrected. The application also automates change detection so data
managers can focus efforts on new or updated data, saving time and
lowering costs.
"Veeva CDB makes collaboration with study partners and data
providers easy, simplifying data transfer and configuration," said
Tonya Arthur, head of data
management, Acelyrin. "Pairing Veeva's clinical data management
platform and our CRO partner's expertise will improve our trial
processes and provide the visibility to make informed decisions
that can positively impact trial outcomes."
Sponsors and contract research organizations (CROs) use Veeva
CDB to ingest and clean clinical data from a variety of system
sources, including EDC systems such as Veeva Vault EDC and Medidata
Rave™, ePRO, and lab data. This allows sponsors to standardize and
optimize processes for effective data management across systems. In
addition, the Veeva CDB Data Provider Program enables qualified
partners with resources to gain operational efficiencies when
delivering data for Veeva CDB customers.
"Data transfers to and from Veeva enable an integrated service
offering that streamlines data delivery for our joint customers
using Veeva CDB and Clinical Ink's comprehensive suite of eCOA,
direct data capture, patient engagement, and digital biomarker
technologies," said Son Ly, vice
president, data services, Clinical Ink.
"As clinical data sources continue to grow and trial complexity
increases, data managers need agile technologies to streamline the
path toward clean data and insights," said Pavel Burmenko, general manager, Veeva CDB.
"With more than 30 data providers supplying study data, Veeva CDB
is gaining momentum, advancing clinical data management for
seamless information exchange and faster access to high-quality
data."
Veeva CDB is part of Veeva Vault Clinical Data Management Suite,
a modern cloud application suite combining EDC, coding, data
cleaning, reporting, randomization, and trial supply
management.
Additional Information
For more on Veeva CDB, visit:
veeva.com/VeevaCDB
For more on Veeva CDB Data Provider Program, visit:
veeva.com/CDBdataprovider
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information,
visit veeva.com/eu.
Veeva Forward-looking Statements
This release contains
forward-looking statements regarding Veeva's products and
services and the expected results or benefits from use of
our products and services. These statements are based on
our current expectations. Actual results could differ
materially from those provided in this release and we have no
obligation to update such statements. There are numerous
risks that have the potential to negatively impact
our results, including the risks and uncertainties disclosed
in our filing on Form 10-Q for the period ended April 30, 2023, which you can
find here (a summary of risks which may impact our
business can be found on pages 37 and 38), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
|
|
Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com
|
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
|
Logo -
https://mma.prnewswire.com/media/1488285/4247738/Veeva_Systems_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/veeva-clinical-database-crosses-200-study-milestone-cuts-time-to-aggregate-and-clean-study-data-by-30-50-301914484.html